A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently With Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs Olaparib (Primary)
- Indications Inflammatory breast cancer
- Focus Therapeutic Use
- 16 Oct 2018 Status changed from not yet recruiting to recruiting.
- 23 Aug 2018 Planned initiation date changed from 10 Aug 2018 to 10 Oct 2018.
- 02 Aug 2018 New trial record